Jubilant Biosys Limited Sustainability Profile
Jubilant Biosys Limited, a prominent player in the biopharmaceutical industry, is headquartered in India and operates extensively across North America, Europe, and Asia. Founded in 2007, the company has established itself as a leader in drug discovery and development services, catering to a diverse range of therapeutic areas including oncology, central nervous system disorders, and infectious diseases. Jubilant Biosys offers a unique blend of integrated services, from early-stage research to clinical development, which distinguishes it in a competitive market. The company’s commitment to innovation and quality has earned it a strong market position, with notable achievements in collaborations with global pharmaceutical firms. With a focus on advancing healthcare solutions, Jubilant Biosys continues to drive progress in the biopharmaceutical landscape.
DitchCarbon Score
How does Jubilant Biosys Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jubilant Biosys Limited's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jubilant Biosys Limited, headquartered in India, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Jubilant Pharmova Limited, which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges from Jubilant Biosys Limited, it is important to note that emissions data and performance metrics may be inherited from its parent company, Jubilant Pharmova Limited. This relationship suggests that any climate initiatives or targets may be aligned with those of Jubilant Pharmova, although specific details are not provided. As a part of the broader industry context, companies like Jubilant Biosys Limited are increasingly expected to adopt science-based targets and participate in initiatives such as the Carbon Disclosure Project (CDP). However, without specific data or commitments from Jubilant Biosys, it remains unclear how they are addressing their carbon footprint or contributing to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Jubilant Biosys Limited's Industry?
How Carbon Intensive is Jubilant Biosys Limited's Location?
Jubilant Biosys Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jubilant Biosys Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
